PODD — Insulet Corporation stock price and chart

PODD

$146.51-6.16%

as of close, Nov 6, 2026

☾ AH $146.51 -6.16%

Insulet CorporationStock · HealthcareS&P 500 Equal Weight · 0.2% of RSPNasdaq Composite · 0.02% of ONEQS&P 500 · 0.02% of SPYRussell 1000 · 0.02% of IWBRussell 3000 · 0.01% of IWVUS Stock Market · 0.01% of VTIMSCI ACWI · 0.01% of ACWIMSCI World · 0.01% of URTH

PeersGMEDSNNPENZBHGKOSDXCM

Share this page

Head-to-head:Compare with GMED or any ticker →

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEEEEEEEEEEEEEEEEEEEE

20162019202120242026

50.0100.0150.0200.0250.0300.0350.0010.0M20.0M$146.51

2026-11-06

Price$146.51

MA20$147.58

MA50$219.53

Vol8.9M

Data provided bySource: Twelve Data

What would $1,000 invested in PODD be worth today? →

PODD returns: By year · By month · By week · Trailing

Key stats#

Data provided bySource: Twelve Data

Price data

Price: $146.51
YTD price return: -48.46%
YTD total return: -48.46%
Market cap: 10.2B2016-12 2.2B2026-11 10.2B+369.7% over the window
Enterprise value: 10.6B
Shares outstanding: 69.4M2016-09 57.4M2026-09 69.4M+20.8% over the window
52W low: $126.40
52W high: $354.88
From 52W high: -58.72%
From 52W low: +15.91%
52W range: 9%$126–$355
Beta: 1.10

Volume

Rel volume: 0.99×
30D volume: 1.6M
30D $ vol: 224.5M

Insider trading

Insider net 1WNo open-market insider purchase or sale with a transaction date in the last 7 days, as filed on Form 4.: none
Insider net 1MNo open-market insider purchase or sale with a transaction date in the last 30 days, as filed on Form 4.: none
Insider net 3M1 insider-day of buying ($162K) and 0 of selling (no priced lot) in the last 91 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: +$162K
Insider net 1Y5 insider-days of buying ($2.6M) and 1 of selling ($60K) in the last 365 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: +$2.5M

Form 4 transactions by trade date, as filed; latest on file 2026-08-21.

Fundamentals

Sales (ttm): 3.2B2016-09 347.2M2026-09 3.2B+818.5% over the window
Sales/share: $45.972016-09 $6.052026-09 $45.97+660.4% over the window
EPS (ttm): $6.132016-12 -$0.482026-09 $6.13-1377.3% over the window
FCF (ttm): 241.2M2016-09 -45.4M2026-09 241.2M-630.8% over the window
FCF/share: $3.482016-09 -$0.792026-09 $3.48-539.4% over the window
Book value/share: $22.762016-09 $1.132026-09 $22.76+1908.1% over the window
Net margin: 13.45%2016-09 -13.6%2026-09 13.4%-199.1% over the window
ROE: 27.15%2016-09 -72.3%2026-09 27.2%-137.5% over the window
ROA: 12.56%2016-09 -10.4%2026-09 12.6%-220.8% over the window
Debt / equity: 0.60×2016-09 5.052026-09 0.60-88.2% over the window
Current ratio: 2.512016-09 6.672026-09 2.51-62.4% over the window

Growth (CAGR, ttm) · 10Y

Sales: +26.48%2025-09-30 → 2026-09-302.5B → 3.2B (+26.5% total)+26.99%2023-09-30 → 2026-09-301.6B → 3.2B (+104.8% total)+25.16%2021-12-31 → 2026-09-301.1B → 3.2B (+190.2% total)+24.83%2016-09-30 → 2026-09-30347.2M → 3.2B (+818.5% total)
Net income: +74.23%2025-09-30 → 2026-09-30246.2M → 428.8M (+74.2% total)+52.87%2023-09-30 → 2026-09-30120M → 428.8M (+257.3% total)n/an/a
FCF: -40.83%2025-09-30 → 2026-09-30407.5M → 241.2M (-40.8% total)+96.45%2023-09-30 → 2026-09-3031.8M → 241.2M (+658.5% total)n/an/a
Shares: -1.39%2025-09-30 → 2026-09-3070.3M → 69.4M (-1.4% total)-0.22%2023-09-30 → 2026-09-3069.8M → 69.4M (-0.7% total)+0.12%2021-09-30 → 2026-09-3069M → 69.4M (+0.6% total)+1.91%2016-09-30 → 2026-09-3057.4M → 69.4M (+20.8% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +80.30%2025-09-30 → 2026-09-30$3.40 → $6.13 (+80.2% total)+53.90%2023-09-30 → 2026-09-30$1.68 → $6.13 (+264.6% total)n/an/a
Sales/share: +28.26%2025-09-30 → 2026-09-30$35.85 → $45.97 (+28.2% total)+27.27%2023-09-30 → 2026-09-30$22.30 → $45.97 (+106.2% total)+25.10%2021-12-31 → 2026-09-30$15.87 → $45.97 (+189.6% total)+22.49%2016-09-30 → 2026-09-30$6.05 → $45.97 (+660.4% total)
FCF/share: -40.00%2025-09-30 → 2026-09-30$5.79 → $3.48 (-40.0% total)+96.88%2023-09-30 → 2026-09-30$0.46 → $3.48 (+663.5% total)n/an/a
Book value/share: +15.71%2025-09-30 → 2026-09-30$19.68 → $22.76 (+15.7% total)+37.79%2023-09-30 → 2026-09-30$8.70 → $22.76 (+161.6% total)+25.82%2021-09-30 → 2026-09-30$7.22 → $22.76 (+215.3% total)+34.99%2016-09-30 → 2026-09-30$1.13 → $22.76 (+1908.1% total)
Price: -54.72%2025-11-06 → 2026-11-06$323.40 → $146.51 (-54.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-2.67%2023-11-06 → 2026-11-06$158.92 → $146.51 (-7.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-13.80%2021-11-05 → 2026-11-06$308.00 → $146.51 (-52.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+15.31%2016-11-04 → 2026-11-06$35.23 → $146.51 (+315.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: -54.72%2025-11-06 → 2026-11-06$323.40 → $146.51 (-54.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-2.67%2023-11-06 → 2026-11-06$158.92 → $146.51 (-7.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-13.80%2021-11-05 → 2026-11-06$308.00 → $146.51 (-52.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+15.31%2016-11-04 → 2026-11-06$35.23 → $146.51 (+315.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 23.9×2016-12 -45.952026-11 23.70-151.6% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 17.3×2016-12 -112.782026-11 17.29-115.3% over the window
Fwd P/E: 20.2×
P/S (ttm)Market cap ÷ TTM revenue.: 3.2×2016-12 6.232026-11 3.19-48.9% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 6.4×2016-12 33.242026-11 6.44-80.6% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 42.1×2016-12 -47.622026-11 42.14-188.5% over the window
EV/EBITDA (fy): 15.3×
EV/Sales (ttm): 3.3×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 2.37%2016-09 -2.1%2026-09 2.7%-226.9% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-09-30) ÷ shares_at(2025-09-30) = 1 − 69.4M ÷ 70.3M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 1.39%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (1.39%) + dividends paid over that year ($0) ÷ market_cap_at(2025-09-30) ($21.7B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 1.39%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($300M) ÷ today's market cap ($10.2B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 2.95%2016-09 -0.3%2026-09 3.3%-1368.1% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $300M + TTM dividends $0) ÷ today's market cap ($10.2B). Same caveat as the cash buyback yield.: 2.95%2016-09 -0.3%2026-09 3.3%-1368.1% over the window

Vs own 10Y history

P/E: 1st
P/OI: 1st
P/S: 1st
P/B: 1st
P/FCF: 15th

Bar = where today’s multiple sits in PODD’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-06#

Data provided bySource: Twelve Data

-6.16%

-2.12%

+8.74%

+5.18%

YTD

-48.46%

-54.70%

-52.43%

-6.16%

-2.12%

+8.74%

+5.18%

YTD

-48.46%

-54.70%

-52.43%

Fundamentals#

Revenue

5Y CAGR +24.5%10Y CAGR +26.2%YoY +19.2%

$3.2B TTM$842M Q3 '26

FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR +55.9%10Y n/mYoY +61.3%

$587.9M TTM$189.8M Q3 '26

FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

EPS (diluted)

5Y CAGR +103.4%5Y CAGR +103.4%YoY +63.7%

$6.13 TTM$2.03 Q3 '26

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m10Y n/mYoY −34.9%

$241.2M TTM$61.6M Q3 '26

FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $509M, capex −$267.8M

Q3 2026: operating cash flow $123.5M, capex −$61.9M

Shares (diluted)

5Y +9.0%5Y +9.0%YoY −1.7%

69.9M TTM69.5M Q3 '26

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

Net income

5Y CAGR +105.2%10Y n/mYoY +61.1%

$428.8M TTM$141.1M Q3 '26

FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

Full PODD financials →

About Insulet#

Data provided bySource: Twelve Data

Insulet Corporation is a medical device company focused on insulin delivery and diabetes management. Its flagship Omnipod platform includes wearable, tubeless insulin management systems designed to deliver continuous insulin without traditional pump tubing or multiple daily injections. The product line includes Omnipod 5, Omnipod DASH, and the Classic Omnipod, along with related pods, controllers, and diabetes management software that support day-to-day glucose control. Insulet also works with selected partners to adapt its Pod technology for the subcutaneous delivery of non-insulin therapies in other medical areas. Headquartered in Acton, Massachusetts, Insulet serves patients and healthcare providers across multiple international markets through direct sales and distribution channels.

Acton, MA·5,400 employees·Medical Devices·insulet.com·As of Oct 28, 2026

Recent filings#

Nov 4Earnings · Earnings release — EPS $1.99 vs $1.59 est. (+25.2%); revenue $842.0M (+19% y/y) 6.6%
Aug 21Insider buy · McEvoy Ashley (President and CEO · Director) bought 1,100 shares for $162K at $147.47
Aug 5Earnings · Earnings release — EPS $1.66 vs $1.44 est. (+15.3%); revenue $801.7M (+24% y/y) 20.1%

All filings and insider trades →

ETFs holding PODD#

31 of the 193 ETFs ChartRow carries live hold PODD. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

Fund	Name	Filed weight
VBK	Vanguard Small-Cap Growth ETF	0.3%
IWP	iShares Russell Mid-Cap Growth ETF	0.3%
RSP	Invesco S&P 500 Equal Weight ETF	0.2%
XLV	Health Care Select Sector SPDR Fund	0.2%
VHT	Vanguard Health Care ETF	0.1%
VB	Vanguard Small-Cap ETF	0.1%
IWR	iShares Russell Midcap ETF	0.1%
SCHG	Schwab U.S. Large-Cap Growth ETF	0.0%

Data provided bySource: Twelve Data

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+16.98%	-0.79%
JNJ	Johnson & Johnson	+8.42%	+1.43%
ABBV	AbbVie Inc.	+9.23%	+1.07%
MRK	Merck & Co. Inc.	+3.37%	-0.14%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+4.74%	-0.40%
NVS	Novartis AG	+15.46%	+0.38%
TMO	Thermo Fisher Scientific Inc.	+5.81%	+2.63%
AMGN	Amgen Inc.	+14.36%	+0.03%

Head-to-head:Compare with GMED or any ticker →

PODD — Insulet Corporation price, chart and key statistics

Key stats#

Price data

Volume

Insider trading

Fundamentals

Growth (CAGR, ttm) · 10Y

Per-share growth (CAGR, ttm) · 10Y

Valuation

Vs own 10Y history

Performance · price returntotal return · as of 2026-11-06#

Fundamentals#

Revenue

Operating income

EPS (diluted)

Free cash flow

Shares (diluted)

Net income

About Insulet#

Recent filings#

ETFs holding PODD#

Related Healthcare#